Employers search
About Us
Exelixis is a biotechnology company dedicated to the discovery, development, and commercialization of novel medicines to improve the lives of patients with serious diseases. With a particular focus on oncology, the company engages in rigorous scientific research to bring effective treatments to market. Founded in 1994 and headquartered in Alameda, California, Exelixis has developed a robust pipeline of therapies that address unmet medical needs. Its flagship product, cabozantinib, marketed under the brand name CABOMETYX®, has shown great efficacy in treating forms of cancer such as renal cell carcinoma and hepatocellular carcinoma. The company's commitment to innovation and strategic partnerships underscores its mission to advance cancer care and provide meaningful patient outcomes worldwide.